172 related articles for article (PubMed ID: 21705028)
1. Expression and prognostic value of NDRG2 in human astrocytomas.
Li L; Wang J; Shen X; Wang L; Li X; Liu Y; Shi M; Zhao G; Deng Y
J Neurol Sci; 2011 Sep; 308(1-2):77-82. PubMed ID: 21705028
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of NDRG2 is related to poor overall survival in patients with glioma.
Li W; Chu D; Chu X; Meng F; Wei D; Li H; Sun B
J Clin Neurosci; 2011 Nov; 18(11):1534-7. PubMed ID: 21872476
[TBL] [Abstract][Full Text] [Related]
3. Relationship between SATB1 expression and prognosis in astrocytoma.
Chu SH; Ma YB; Feng DF; Zhang H; Qiu JH; Zhu ZA; Li ZQ; Jiang PC
J Clin Neurosci; 2013 Apr; 20(4):543-7. PubMed ID: 23317753
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer.
Zhao H; Zhang J; Lu J; He X; Chen C; Li X; Gong L; Bao G; Fu Q; Chen S; Lin W; Shi H; Ma J; Liu X; Ma Q; Yao L
BMC Cancer; 2008 Oct; 8():303. PubMed ID: 18940011
[TBL] [Abstract][Full Text] [Related]
5. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.
Mizumatsu S; Tamiya T; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Clin Cancer Res; 1999 Mar; 5(3):551-7. PubMed ID: 10100706
[TBL] [Abstract][Full Text] [Related]
6. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
[TBL] [Abstract][Full Text] [Related]
7. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis.
Korkolopoulou P; Patsouris E; Konstantinidou AE; Pavlopoulos PM; Kavantzas N; Boviatsis E; Thymara I; Perdiki M; Thomas-Tsagli E; Angelidakis D; Rologis D; Sakkas D
Neuropathol Appl Neurobiol; 2004 Jun; 30(3):267-78. PubMed ID: 15175080
[TBL] [Abstract][Full Text] [Related]
9. [Expression of candidate tumor suppressor gene N-Myc downstream-regulated gene 2 in colon cancer].
Chu DK; Zhang J; Shi H; Dong GL; Liu XP; Wang WZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):354-7. PubMed ID: 18636358
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of frizzled 9 in astrocytomas.
Zhang Z; Schittenhelm J; Guo K; Bühring HJ; Trautmann K; Meyermann R; Schluesener HJ
Neuropathol Appl Neurobiol; 2006 Dec; 32(6):615-24. PubMed ID: 17083476
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival.
Li J; Guan HY; Gong LY; Song LB; Zhang N; Wu J; Yuan J; Zheng YJ; Huang ZS; Li M
Clin Cancer Res; 2008 Nov; 14(21):6996-7003. PubMed ID: 18980995
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation.
Goeppert B; Schmidt CR; Geiselhart L; Dutruel C; Capper D; Renner M; Vogel MN; Zachskorn C; Zinke J; Campos B; Schmezer P; Popanda O; Wick W; Weller M; Meyermann R; Schittenhelm J; Harter PN; Simon P; Weichert W; Schirmacher P; Plass C; Mittelbronn M
J Neuropathol Exp Neurol; 2013 Oct; 72(10):933-41. PubMed ID: 24042196
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation-mediated down-regulation of CXCL12 in human astrocytoma.
Zhou W; Jiang Z; Song X; Liu Y; Wen P; Guo Y; Xu F; Kong L; Zhang P; Han A; Yu J
J Neurosci Res; 2008 Oct; 86(13):3002-10. PubMed ID: 18512766
[TBL] [Abstract][Full Text] [Related]
14. Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma.
Söling A; Sackewitz M; Volkmar M; Schaarschmidt D; Jacob R; Holzhausen HJ; Rainov NG
Clin Cancer Res; 2005 Jan; 11(1):249-58. PubMed ID: 15671553
[TBL] [Abstract][Full Text] [Related]
15. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650.
Feng L; Xie Y; Zhang H; Wu Y
Biochem Biophys Res Commun; 2011 Mar; 406(4):534-8. PubMed ID: 21352815
[TBL] [Abstract][Full Text] [Related]
17. Reduced WWOX protein expression in human astrocytoma.
Winardi W; Tsai CY; Chen WT; Tsai HP; Chung CL; Loh JK; Chai CY; Kwan AL
Neuropathology; 2013 Dec; 33(6):621-7. PubMed ID: 23675860
[TBL] [Abstract][Full Text] [Related]
18. DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma.
El-Sitt S; Khalil BD; Hanna S; El-Sabban M; Fakhreddine N; El-Sibai M
Oncol Rep; 2012 Aug; 28(2):511-8. PubMed ID: 22614672
[TBL] [Abstract][Full Text] [Related]
19. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.
Tepel M; Roerig P; Wolter M; Gutmann DH; Perry A; Reifenberger G; Riemenschneider MJ
Int J Cancer; 2008 Nov; 123(9):2080-6. PubMed ID: 18709645
[TBL] [Abstract][Full Text] [Related]
20. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
